Join Us for a Special 90-minute ISMPP U:

Open Access and Medical Publishing

This ISMPP U is open to ALL regardless of ISMPP membership status. 

Wednesday, January 30, 2019
11:00 AM (ET) / 4:00 PM (UK)

Presentation Slides

To listen to the audio and slide presentation, click on the following link:

Approved for 1.5 ISMPP CMPPTM Recertification Credit


Joe Adams, Regional Sales Manager EMEA, Wiley

Ashley Farley, MLIS, Associate Officer of Knowledge & Research Services, Bill & Melinda Gates Foundation

J. Britt Holbrook, PhD, Assistant Professor, Department of Humanities, New Jersey Institute of Technology; Member, Open Access Advisory Panel, European Commission

Valerie Philippon, PhD, Senior Director and Global Head, Scientific Publications, Global Medical Affairs, Shire

David Sampson, MBA, Vice President and Publisher, Publishing, American Society of Clinical Oncology (ASCO)

Alan Thomas, Patient Engagement Advocate; Founder, Ataxia and Me©


LaVerne Mooney, BSc, MPH, DrPH, Director & Team Leader: Publications, CI and Innovation, External Medical Communications, Pfizer; Steering Committee Member, Medical Publishing Insights and Practices (MPIP); Member, Open Pharma

Chris Winchester, DPhil, Chair, ISMPP Board of Trustees (2018–2019); CEO, Oxford PharmaGenesis; Co-founder, Open Pharma

Webinar Overview:

As the principles of open science become more widely adopted by the medical research community, open access publishing is an increasingly debated topic. This debate has highlighted a lack of common understanding of what open access means, how it works and why it is important for different stakeholders.

Authors face a confusing variety of options for open access publishing of their research. Governmental and charitable research funders are increasingly requiring the research they fund to be published open access and Shire became the first pharmaceutical company to require all research it funds to be published open access from the beginning of 2018. However, some journals have policies that limit or prohibit open access publishing options for authors of commercially-funded research.

Furthermore, a group of national research funders with the support of the European Commission have recently committed to Plan S, the key principle of which is that research funded by participating national and European funders must be published open access by 2020. Under the terms of Plan S, hybrid journals that charge authors for open access in addition to subscription fees will not be permitted.

Against this backdrop, publication professionals and those within the scientific community need a clear understanding of open access publishing options and appreciate the implications of research funders' open access policies and Europe's accelerated transition to full and immediate open access via Plan S.

This special ISMPP U session is open to all and may be of interest to those who want to learn more about open access medical publishing. You will have an opportunity to submit questions at the end of the webinar. Please forward this announcement to colleagues. All are welcome!

At the end of this session, participants should be able to:

  • Understand the growing movement towards open access publishing and be aware of the economic considerations and concerns surrounding open access

  • Define key elements of open access publishing options and policies (e.g., gold, green and bronze open access models, article versions, embargo periods, Creative Commons licensing options, funders' open access policies)

  • Understand the perspectives on open access of non-commercial and commercial stakeholders in medical research

  • Be knowledgeable about the changing open access environment and what the future of open access might look like from the perspectives of key stakeholder groups (publisher, funder, researcher, patient and industry)

*Webinar Pre-Reading*:

As a primer to the webinar and to aid understanding of some fundamental open access publishing concepts, we highly encourage attendees to review and read in advance the Open Access Reference site, recently developed by Medical Publishing Insights & Practices (MPIP)

Faculty Bios:

Joe Adams runs the EMEA sales team for direct pharmaceutical sales at Wiley. The main focus of Joe and his team is to enhance the impact of articles and content to develop greater engagement for pharma clients and journals. Joe has a successful background managing teams focusing on larger content solution packages for the pharmaceutical industry. In addition to this Joe manages commercial aspects such as advertising and reprints.

Ashley Farley has worked over the past decade in both academic and public libraries, focusing on digital inclusion and providing access to scholarly content. She has completed her Masters in Library and Information Sciences through the University of Washington’s Information School. Ashley is an Associate Officer of Knowledge and Research Services. In this capacity, she serves on the core Open Access team, focusing on the foundation’s Open Access Policy’s implementation. This includes the development of Chronos, and leading the implementation of Gates Open Research. Other core activities involve supporting the strategic and operational aspects of the foundation’s library. This work has sparked a passion for open access, believing that freely accessible knowledge has the power to improve and save lives.

Valerie Philippon is the Head of Global Publications at Shire, a leading global biotech in rare diseases with medicines in over 100 countries. She leads the publications teams responsible for publications related to all company therapeutic areas (hematology, immunology, oncology, gastrointestinal/internal medicine, neuroscience, ophthalmics, genetic diseases) across various geographies. Valrie has over 20 years of experience in Research, Development, and Medical Communications. She received her Ph.D. in Microbiology from the University Denis Diderot Paris, France and completed a post-doctoral fellowship at Harvard School of Public Health. She has held various Publications and Scientific Communication roles with increasing responsibilities at Idenix, Vertex, AVEO Oncology, and Cubist before joining Shire.

David Sampson is Vice President and Publisher, Publishing for the American Society of Clinical Oncology where he manages a portfolio of journals and meeting publications and heads up licensing. Prior to joining ASCO, he was an Executive Publisher in Elsevier’s health sciences journals division where he had P&L and strategic responsibility for a portfolio of more than 20 journals. He also worked at Lippincott Williams & Wilkins in various leadership roles, including five years as Managing Director of its Asia office in Hong Kong. He was also an Executive Vice President at Conference Archives, now part of CTI Meeting Technology.

Alan Thomas is a patient engagement advocate for rare diseases in general and Ataxia in particular. He is known as the 'rare disease warrior' and, as a patient with a 'life-limiting' rare disease, he can convey the patient engagement message from his point of view in all issues regarding the wellbeing of patients. Alan has established a patient-driven and focused group and campaigns at many levels, including patient forums, local and regional health boards, Welsh/UK government organizations, as well as taking part in many global conferences. He received a nomination from the Bevan Foundation in 2015 in the Health and Wellbeing category. He also founded Ataxia and Me©, an on-line resource for all affected by the condition as well as associated rare diseases and movement disorders.


LaVerne Mooney obtained her BSc degree from Galway University, Ireland and was awarded her Master and Doctor of Public Health degrees from Columbia University Mailman School of Public Health, New York. LaVerne assessed the contribution of genetic and environmental factors to breast and lung cancer at Mailman SPH where she was Assistant Clinical Professor of Public Health, Molecular Epidemiology Group. For the last 11 years, LaVerne has been a Director of Publications in Pfizer Medical where she has concentrated on continuous improvement, publication policy best practices and transparency. LaVerne is currently focusing on innovations in publication technology and policies that can improve access and utility to information, such as reduction of publication cycle times and Open Access. She has represented Pfizer as a Steering Committee Member of the Medical Publication Insights and Practice collaboration, has served on the board of the International Society of Medical Publication Professionals, and is a member of the Open Pharma initiative. LaVerne has published about her research and best publication practices in peer-reviewed literature, and is a coauthor of GPP3.

Chris Winchester is Chief Executive Officer of Oxford PharmaGenesis, an independent HealthScience communications consultancy with a strong heritage in publications. Now in its 21st year, Oxford PharmaGenesis employs over 250 communications professionals in Europe, North America and Asia Pacific. Chris is Chair of ISMPP, a founder of Open Pharma, led the development of the AMWA-EMWA-ISMPP Joint Position Statement on the role of the professional medical writer, and has been involved in collaborative research on the value of professional medical writing support. He has a doctorate in Biochemistry, has co-authored articles in the fields of cardiology, gastroenterology and respiratory medicine, and is an Associate Member of Green Templeton College at the University of Oxford.

Back to top